MedTech Terms
    The authoritative reference
    All terms
    Investment & FinanceStartup Lifecycle

    Preferred Stock

    Class of equity with rights superior to common stock.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Preferred stock is the security class issued to venture investors. It carries a liquidation preference, anti-dilution protection, dividend rights, protective provisions (veto rights over key actions), and often board representation - rights not held by common stockholders.
    What the regulation says
    While preferred stock itself is not directly regulated by MedTech-specific authorities, its implications for company ownership and control can indirectly affect regulatory compliance, particularly regarding accountability for quality management systems and reporting requirements. For instance, changes in company control due to preferred stock provisions might impact the designated "person responsible for regulatory compliance" under EU MDR (Article 15) or the "management representative" described in 21 CFR 820.20(b)(3).

    What this means in practice

    Each round (Series Seed, A, B, C…) typically issues a new series of preferred with its own preference and rights, stacked in reverse order of issuance.

    Examples

    • A MedTech startup's Series B preferred stockholders use their veto rights to block an acquisition offer, thereby prolonging the time before the company has sufficient resources to upgrade its outdated quality management software to comply with 21 CFR Part 11.
    • A company's preferred stock agreement includes a provision that requires unanimous board approval for any major capital expenditure, delaying the purchase of a new manufacturing line needed to meet increased demand for a life-saving device and maintain production quality.
    • During a product recall, preferred stockholders exercise their protective provisions to delay public communication, conflicting with the urgent reporting requirements mandated by regulatory bodies like the FDA under 21 CFR 806.
    Common pitfalls
    • •A common pitfall is overlooking how preferred stock provisions granting veto rights can delay or complicate critical regulatory decisions, such as product recalls or significant quality system changes.
    • •Companies sometimes fail to communicate changes in ownership or control stemming from preferred stock agreements to regulatory bodies, which can be a reporting requirement in some jurisdictions.
    • •Misunderstanding the impact of liquidation preferences on a company's financial stability can indirectly affect its ability to maintain a robust quality management system and ensure product safety.
    • •Ignoring the potential for preferred stockholder influence to conflict with the independence required for certain regulatory roles, such as internal auditors or quality managers, is another mistake.

    Frequently asked questions

    Preferred stock provisions, particularly those granting control or veto rights, can influence a company's decision-making processes, which in turn affect its ability to meet regulatory deadlines, implement corrective actions, or respond to regulatory inquiries. It indirectly affects the regulatory obligations of a MedTech company as the distribution and terms of preferred stock can influence funding, and funding affects QMS maturity and resource availability.

    Cross-references

    Part of

    A larger framework or document this term belongs to.

    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    NVCA·1SVB·1PitchBook·1
    1. 1
      NVCA model docs
      Verified
      NVCAnvca.org
    2. 2
      Silicon Valley Bank - Healthcare Reports
      Verified
      SVBsvb.com
    3. 3
      PitchBook - MedTech Coverage
      Verified
      PitchBookpitchbook.com

    Inline markers like [1] jump to the matching reference above.